Egis Gyogyszergyar Zrt.

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Nyrt

Egis Gyogyszergyar Rt.

Balázs Volk

Gyula Simig

Tibor Mezei

József Barkóczy

László Szlávik

Márta Porcs-Makkay

Bálint Nyulasi

Zoltán Varga

Kálmán Nagy

Gábor Németh

György Lévay

Katalin Pallagi

Adrienn Keszthelyi

István Gacsályi

Gyula Lukács

Krisztina Móricz

Gábor Gigler

László Gábor Hársing

Enikó Molnár

András Egyed

Csilla Leveleki

Mátyás Milen

Gábor Berecz

András Mravik

Attila Virág

Tamás Nagy

Rita Kapillerné Dezsöfi

Nóra Sziray

Károly Lozsi

Beatrix Bali

Daniel Ulej

András Balázs Dancsó

Zsuzsanna Szokol

Regina Némethné Csillag

Gábor Szénási

Györgyi Vereczkeyné Donáth

Zsuzsanna Szent-Királlyi

Gyuláné Körtvélyessy

Tamás Gregor

János Szulágyi

Tibor Szabó

Éva Pécsi

Judit Broda

Imre Kapui

György Clementis

László Pongó

Hajnalka Kompagne

Angéla Pandur

Norbert Mesterházy

János Pethö

Gábor Szenasi

György Ruzsics

Endréné Flórian

Ferenc Bertha

Enikö Molnár

Péter Slégel

József Debreczeni

Mária Vajjon

Valéria Hofmanné Fekete

György Krasznai

Judit HALÁSZ

ÉVa SzabÓ

Katalin KÁTAINÉ Fadgyas

Mária TÓTHNÉ Lauritz

András DancsÓ

Róbert KORMÁNY

Imre KIRÁLY

László Palotai

Róbert Gudor

János Levente HÉDER

Ede László MÁRVÁNYOS

Balázs Peregi

Györgyi KOVÁNYINÉ Lax

László József HEGEDÜS

András Boza

Mária Júlia TÁBORINE TÓTH

György MOROVJÁN

Ferenc Lóránt Bartha

Maria TÓTHNÉ Lauritz

Tibor SzabÓ

Mária KOVÁCS

Laszló PongÓ

Jozsef BARKÓCZY

Feren Bartha

Valéria HoffmannÉ Fekete

János Imre

Imre KÖHEGYI

Elemér Fogassy

Ildikó Nagyné Gyönös

István Gacsalyi

József Schindler

Katalin Nagy

Balázs Havasi

ÉVa Sipos

ZnClco-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2, ZnClco-crystal of (S)-(−)-blarcamesine hydrochloride of formula 2and ZnClco-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.

Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X=I, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Method for the production of lumateperone and its salts

The object of the present invention is a process for preparing the 2-acetoxi-5-(2-fluor-&#x3b1;-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-thieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts from crystalline 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof.

Process for preparing pharmaceutical compounds and intermediate compounds

The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein Rrepresents fluorine or chlorine atom or Calkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein Rrepresents Calkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy. 

Process for the preparation of pharmaceutical intermediates

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favorable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cadiovascular system. 

Piperazine derivatives of alkyl oxindoles

The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein Rstands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; Rrepresents hydrogen or halogen; Rdenotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying one or two halogen substituent(s); Rstands for alkyl having 1-7 carbon atom(s); Rrepresents a group of the general Formula (II a) or (II b), wherein Q and W each represents nitrogen or CH; R, Rand Reach stands for hydrogen, halogen, trifluoromethyl, alkyl or alkoxy having 1-7 carbon atom(s), or Rand Rtogether represent ethylenedioxy; m is 0, 1, or 2; a is a single, double or triple bond; n is 0, 1 or 2; and pharmaceutically acceptable acid addition salts thereof which are useful in the treatment or prophylaxis of diseases of the central nervous system, the gastrointestinal system and the cardiovascular system. 

Piperazine derivatives of dialkyl oxindoles

Growing community of inventors

Budapest, Hungary

Balázs Volk